In a video for MD Magazine, researchers talk in depth about current and developing agents for multidrug-resistant (MDR) bacteria.
In recent years, we’ve been very fortunate to have several agents approved for the treatment of patients with serious gram-negative infections. One of those is ceftazidime/avibactam. Ceftazidime/ avibactam is currently FDA approved for the treatment of adults with complicated urinary tract infections when combined with metronidazole and treatment of adults with complicated intra-abdominal infections, and, most recently, it’s indicated for the treatment of adults with hospital-acquired pneumonia and ventilator-associated pneumonia.
This is an important agent in our armamentarium. A lot of our use right now at our institution is off-label, and really, we target it for patients who have serious infections with KPC-producing Klebsiella pneumoniae. So, really, it has become a go-to agent for CRE at our institution.